Astria TherapeuticsATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 78
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
3% more funds holding
Funds holding: 110 [Q4 2024] → 113 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.62% less ownership
Funds ownership: 103.81% [Q4 2024] → 103.18% (-0.62%) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 36
41% less capital invested
Capital invested by funds: $524M [Q4 2024] → $311M (-$213M) [Q1 2025]
86% less call options, than puts
Call options by funds: $5K | Put options by funds: $36K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Cantor Fitzgerald Timur Ivannikov 100% 1-year accuracy 2 / 2 met price target | 1,087%upside $47 | Overweight Reiterated | 14 May 2025 |
Cantor Fitzgerald Steven Seedhouse 0% 1-year accuracy 0 / 8 met price target | 1,087%upside $47 | Overweight Initiated | 29 Apr 2025 |
Wedbush Laura Chico 23% 1-year accuracy 10 / 44 met price target | 607%upside $28 | Outperform Maintained | 12 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 75 / 369 met price target | 304%upside $16 | Buy Reiterated | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 49% 1-year accuracy 30 / 61 met price target | 557%upside $26 | Market Outperform Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 4 articles about ATXS published over the past 30 days









